Samsung Pharm Continues Long-Term Administration of PSP Treatment GV1001... Expanding Patient Access to Therapy View original image

On March 26, Samsung Pharm announced that patients who participated in the clinical trial of the progressive supranuclear palsy (PSP) treatment "GV1001" are continuing to receive additional doses in a stable manner through the Korea Ministry of Food and Drug Safety’s compassionate use program.


The compassionate use program allows the use of investigational drugs for treatment purposes when patients are suffering from life-threatening, severe diseases or have no alternative treatment options available.


This case was initially conducted by GemVax & KAEL under approval from the Korea Ministry of Food and Drug Safety for between two and fewer than 25 patients. Recently, the sponsor for this program has changed to Samsung Pharm.


According to the company, all 24 patients eligible for registration through the compassionate use program have completed participation. Most of these patients have now maintained long-term treatment for more than two years, including the previous 18-month clinical trial period.


Progressive supranuclear palsy is a rare disease with an average survival period of only about 6 to 7 years, and currently, there is no definitive treatment available.


A Samsung Pharm representative stated, "It is highly significant that PSP patients have been able to continue treatment stably for more than two years," adding, "We will continue to support uninterrupted treatment and steadily advance follow-up clinical trials to provide more patients with real therapeutic opportunities."



Meanwhile, Samsung Pharm has recently secured the rights to clinical development and commercialization of GV1001 in four major Asian countries, including Korea, through a technology transfer agreement with GemVax. The company has also applied for conditional product approval from the Korea Ministry of Food and Drug Safety.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing